Fertility Decoded

PGT-A (preimplantation genetic testing for aneuploidy)

A biopsy of the embryo to check it has the right number of chromosomes before transfer.

The verdict

Not recommended as a routine add-on; it may reduce your chance of a baby (especially under 35), though it can reduce the chance of miscarriage.

Evidence positions on PGT-A (preimplantation genetic testing for aneuploidy) from HFEA, ESHRE, NICE and ISAR
BodyPosition
HFEA
  • Red — may reduce effectivenessfor chance of a baby (most patients)
  • Green — effectivefor reducing miscarriage (most patients)
  • Grey — insufficient evidencefor either outcome in older women
ESHRENot for routine use

Not recommended for routine clinical use; specific groups (e.g. older patients) may benefit, but routine use isn't recommended without more evidence.

Source
NICEDo not offer (2026)

NG257 1.48.1: do not offer PGT-A as part of fertility treatment to improve live birth rates.

Source
ISARRole for age 36–40 & known-cause RPL

ISAR PGT consensus: recommended for advanced maternal age (36–40) and repeated pregnancy loss with a known cause; not recommended for under-35 good-prognosis, unexplained RPL, or low-AMH patients; no evidence of efficacy in recurrent implantation failure.

Source

Cochrane evidence base

2020 review: insufficient evidence of a difference in cumulative live birth; possible miscarriage reduction on the first transfer only, cumulative data scarce.

In India

~₹23,000–30,000 per embryo (some clinics ₹25,000–50,000+ total), on top of base IVF.

Does PGT-A improve my chance of having a baby?
For most patients, no. HFEA rates it red for improving your chance of a baby because it is a selection tool that reduces the embryos available and can lengthen the time to conception; NICE advises not offering it to improve live birth rates.
Is PGT-A ever worthwhile?
It can reduce the chance of miscarriage (HFEA rates it green for that), and the Indian society (ISAR) sees a role for women aged 36–40 or with known-cause recurrent pregnancy loss. It is not recommended for younger, good-prognosis patients.

Sources

Take this further

Last reviewed .